NCT06524544 2026-03-18
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
18 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT07322263 2026-03-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Not yet recruiting
NCT05848011 2026-03-16
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Active not recruiting
NCT06863272 2026-03-16
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07225946 2026-03-13
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06488222 2026-03-11
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
Phase 2 Recruiting
NCT07287150 2026-03-05
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05538663 2026-03-02
BRIDGE
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT05644041 2026-02-27
Intravesical Gem/Doce in Patients With NMIBC
University of Arizona
Phase 2 Recruiting
NCT04895709 2026-02-25
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07419295 2026-02-19
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting